Michael Girardi, MD, FAAD, Evans Professor of Dermatology, has been awarded the 2025 Translational Research Program Award from The Leukemia & Lymphoma Society to support his research developing new treatments for T-cell lymphoma. This prestigious award supports groundbreaking research that shows high promise of moving laboratory discoveries to clinical application.
Girardi, who is also co-director of the Cutaneous Lymphoma Group, director of the Photopheresis Unit, and director of the Phototherapy Unit at Yale, will focus his research on developing novel approaches to the diagnosis and treatment of cutaneous T-cell lymphoma (CTCL) and innovation in immunotherapy and nanotechnology for cancer treatment. Girardi has published over 200 scientific manuscripts and book chapters and has received multiple innovation awards including the Yale Blavatnik Innovation Award and the American Cancer Society’s BrightEdge award.
The goal of this translational award is to reduce the time between laboratory findings and actual treatment, putting research on the bench-to-bedside fast track when it comes to finding better treatment and cures for blood cancers. The Leukemia & Lymphoma Society is the world's largest nonprofit health organization dedicated to funding blood cancer research and providing education and patient services.